Journal article
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
Abstract
Background Sorafenib is an oral multikinase inhibitor that blocks cell proliferation via the ERK pathway and angiogenesis via the VEGF pathway. This phase II trial was conducted to determine the efficacy and tolerability of sorafenib for the treatment of patients with metastatic urothelial cancer (UC) who had not had prior chemotherapy for advanced disease. Patients and Methods Seventeen chemo-naïve UC patients with adequate performance status …
Authors
Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ
Journal
Investigational New Drugs, Vol. 29, No. 5, pp. 1045–1049
Publisher
Springer Nature
Publication Date
October 2011
DOI
10.1007/s10637-010-9408-4
ISSN
0167-6997